Our study showed that the target genes of circ-Med14 were part of the MAPK and apelin signaling pathways, in addition to the progression of insulin resistance, hypertrophic cardiomyopathy, and chronic myeloid leukemia (CML). This evidence concerns the gene APLN and chronic myelogenous leukemia, BCR-ABL1 positive.